India’s weight-loss drug market is heating up as top domestic drugmakers roll out generic versions of semaglutide, a popular medication for weight management and diabetes. This move comes swiftly after the patent expiry, with generics priced significantly lower, triggering intense competition.
Within a day of the patent lapsing, major players have launched their versions, offering prices 50-90% cheaper than the original. This aggressive pricing strategy is expected to rapidly expand access to the drug while intensifying the battle for market share.
The entry of generics is poised to disrupt the existing market dynamics, potentially benefiting patients through reduced costs and increased availability. However, it also presents challenges for companies as they navigate pricing pressures and seek to establish their position in this competitive landscape.
Industry analysts anticipate a scramble among pharmaceutical companies to capture a significant share of India’s burgeoning weight-loss and diabetes market. The long-term implications of this generic wave will depend on factors such as brand recognition, distribution networks, and marketing strategies.
About the Author
